AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Core Insights - AIM ImmunoTech Inc. is advancing its clinical development programs, particularly in high-value areas such as pancreatic cancer, with significant milestones expected in the next 18 months [1][2] Financial Highlights - As of December 31, 2024, AIM reported cash, cash equivalents, and marketable investments of $4.0 million, a decrease from$13.1 million as of December 31, 2023 [16] - Research and development expenses for the year ended December 31, 2024, were $6.2 million, down from$10.9 million in 2023 [16] - General and administrative expenses for the year ended December 31, 2024, were $13.7 million, compared to$21.1 million in 2023 [16] Upcoming Milestones - In the area of metastatic pancreatic ductal adenocarcinoma, a Phase 1b/2 trial combining Ampligen with AstraZeneca's Durvalumab is expected to enroll the last patient by Q2/Q3 2026 [4] - For refractory melanoma, a Phase 2 trial involving Ampligen is underway, with plans to study Ampligen in combination with AstraZeneca's FluMist as an intranasal vaccine for influenza [5] - A Phase 1/2a study for stage 4 triple-negative breast cancer is expected to complete enrollment by Q2 2026 [7] - In advanced recurrent ovarian cancer, a Phase 2 study is set to complete in H1 2025 [8] Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, with its lead product being Ampligen, a first-in-class investigational drug [13]